# OnCo record tazemetostat-doxorubicin-es (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/tazemetostat-doxorubicin-es/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "tazemetostat-doxorubicin-es", "NCT04204941" ;
  schema:name "Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)"@en ;
  schema:description "The attempt to move the EZH2 inhibitor tazemetostat into first-line epithelioid sarcoma alongside doxorubicin; the safety run-in enrolled 25 patients and the study was stopped, leaving the accelerated approval without its confirmatory trial."@en ;
  schema:url <https://onco.cc/trials/tazemetostat-doxorubicin-es/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04204941>, <https://doi.org/10.1016/S1470-2045(20)30451-4> ;
  onco:status "withdrawn" ;
  onco:tag "owner-request" ;
  onco:phase "1" ;
  schema:startDate "2019-12-19" ;
  onco:cancers <https://onco.cc/cancers/epithelioid-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:drugs <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/ipsen/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gounder-lancet-oncol/> .